The number of people with sickle cell disease in the United States: National and state estimates, American Journal of Hematology, vol.85, pp.77-85, 2010. ,
DOI : 10.1002/ajh.21570
Global epidemiology of haemoglobin disorders and derived service indicators, Bulletin of the World Health Organization, vol.2008, issue.6, pp.480-487, 2008. ,
DOI : 10.2471/BLT.06.036673
A Specific Chemical Difference Between the Globins of Normal Human and Sickle-Cell An??mia H??moglobin, Nature, vol.110, issue.4537, pp.792-796, 1956. ,
DOI : 10.1042/bj0590653
Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children, PEDIATRICS, vol.122, issue.6, pp.1332-1374, 2008. ,
DOI : 10.1542/peds.2008-0441
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease, Blood, vol.110, issue.7, pp.2749-56, 2007. ,
DOI : 10.1182/blood-2007-03-079665
Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future, Bone Marrow Transplantation, vol.12, issue.2 ,
DOI : 10.1111/j.1365-2141.2006.06486.x
URL : http://www.nature.com/bmt/journal/v41/n2/pdf/1705943a.pdf
, Bone Marrow Transplant, vol.41, pp.109-126, 2008.
Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies, Bone Marrow Transplantation, vol.91, issue.7, pp.547-50, 2003. ,
DOI : 10.1002/1097-0142(20010101)91:1+<274::AID-CNCR18>3.0.CO;2-E
Availability of related donors for bone marrow transplantation in sickle cell anemia, Am J Pediatr Hematol Oncol, vol.16, pp.27-36, 1994. ,
Genetically engineered cures: gene therapy for sickle cell disease Renaissance of sickle cell disease research in the genome era, pp.295-310, 2007. ,
Retroviral transfer of a human beta-globin/delta-globin hybrid gene linked to beta locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease., Proceedings of the National Academy of Sciences, vol.92, issue.7, pp.3014-3022, 1995. ,
DOI : 10.1073/pnas.92.7.3014
Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease, Current Gene Therapy, vol.15, issue.1, pp.64-81, 2015. ,
DOI : 10.2174/1566523214666141127095336
The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy, Journal of Clinical Investigation, vol.119, issue.4, pp.964-75, 2008. ,
DOI : 10.1172/JCI37630DS1
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, Journal of Clinical Investigation, vol.118, issue.9, pp.3143-50, 2008. ,
DOI : 10.1172/JCI35798DS1
Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration, Science, vol.300, issue.5626, pp.1749-51204, 2003. ,
DOI : 10.1126/science.1083413
Interim results from a phase 1/2 clinical study of LentiGlobin gene therapy for severe sickle cell disease Sickle cell disease in Saudi Arabia: the phenotype in adults with the Arab-Indian haplotype is not benign Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia Outcomes of gene therapy for severe sickle disease and beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex vivo with a lentiviral beta AT87Q-globin vector Update of results from the Northstar Study (HGB-204): a phase 1/2 study of gene therapy for beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex-vivo with a lentiviral beta AT87Q-globin vector (LentiGlobin BB305 drug product), Phase 1/2 Clinical Study. Presented at the 58th Annual Meeting of the Presented at the 58th Annual Meeting of the al. Transfusion independence and HMGA2 activation after gene therapy of human ?-thalassaemia, pp.597-604, 2001. ,
, Copyright © 2017 Massachusetts Medical Society
, For personal use only. No other uses without permission, 2017.